FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to multicorpuscular dosed composition with regulated release of lamotrigin or its pharmaceutically acceptable salt, presented as tablet or capsule containing (a) composition nucleus particles, containing lamitrigin within dosage range 25 to 600 mg; (b) specified composition nucleus particles coated with polymer regulating release rate; and (c) quick-breaking vehicle enabling particles to disperse in aqueous environment, yet specified vehicle is taken in amount 1% to 10% of composition total, and specified dosed composition is characterised with specific release profile. Besides, invention refers to production of specified composition, as well as to application and therapeutic methods for CNS disorders by this composition.
EFFECT: improved therapeutic conditions and schedule.
28 cl, 14 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONTROLLED-RELEASE HYDROCODON COMPOSITION | 2001 |
|
RU2253452C2 |
| TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS | 2014 |
|
RU2674345C2 |
| ORAL DOSAGE FORMS OF TOFACITINIB WITH CONTINUOUS RELEASE | 2014 |
|
RU2790166C2 |
| ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS | 2015 |
|
RU2764569C2 |
| DELAYED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING ASPARAGINATES | 2016 |
|
RU2632713C2 |
| SYNERGETIC ANALGETIC COMBINATION OF OPIOID ANALGETIC AGENT AND CYCLOOXYGENASE-2 INHIBITOR | 1998 |
|
RU2232600C2 |
| MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
| DRUG DELIVERY SYSTEMS CONTAINING WEAKLY ALKALINE SELECTIVE 5-HT SEROTONINE ANTAGONIST AND ORGANIC ACIDS | 2007 |
|
RU2490012C2 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
